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Two-stage analyses of genome-wide association studies have been proposed as a means to improving power for designs including family-
based association and gene-environment interaction testing. In these analyses, all markers are first screened via a statistic thatmay not be
robust to an underlying assumption, and the markers thus selected are then analyzed in a second stage with a test that is independent
from the first stage and is robust to the assumption in question. We give a general formulation of two-stage designs and show how one
can use this formulation both to derive existing methods and to improve upon them, opening up a range of possible further applica-
tions. We show how using simple regression models in conjunction with external data such as average trait values can improve the
power of genome-wide association studies. We focus on case-control studies and show how it is possible to use allele frequencies derived
from an external reference to derive a powerful two-stage analysis. An illustration involving the Wellcome Trust Case-Control Consor-
tium data shows several genome-wide-significant associations, subsequently validated, that were not significant in the standard analysis.
We give some analytic properties of the methods and discuss some underlying principles.Introduction
Although there is consensus on simplemethods of primary
statistical analysis in genome-wide association studies
(GWASs), there have been continuing efforts to develop
more powerful approaches as the vast extent of polygenic
heritability of complex traits has become apparent.1,2
A strategy that has received much attention is that
of reducing the inherent multiplicity by performing a
two-stage analysis. In the first stage, a preliminary
screening of markers is performed, and this is followed
by a final analysis on a subset of markers with a reduced
multiple-testing adjustment. For example, it can be cost
efficient to perform the full GWAS on a subset of the study
sample but to hold back the remainder for a confirmatory
analysis of the most promising markers.3,4 Alternatively,
one can analyze all data in different ways at each stage
and use each analysis to reduce the number of tests
performed.5,6
In this paper we are concerned with a class of two-stage
approaches in which a single sample is analyzed twice with
two independent statistics. In the first pass, the data are
analyzed with a statistic that is valid only under some
underlying assumptions. The markers that are selected
from this stage are then analyzed in a second pass via an
independent test that is robust to the assumptions in
question. Because the statistics in the two stages are inde-
pendent by construction, the final multiplicity depends
only on the markers tested in the second stage; these
markers are potentially much fewer than those in the first
stage.
This approach was initiated in the context of family-
based association tests of quantitative traits.7 The standard1Medical Research Council Biostatistics Unit, Institute for Public Health, Ca
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stratification, but a first-stage analysis can be performed
with between-family information that might be con-
founded by stratification. Reasonable gains in power over
standard GWAS analysis have been postulated,8 and the
method has been adapted for binary traits.9
A related approach has been developed for tests of gene-
environment interaction.10 The traditional test compares
the gene-environment association in cases to the same
quantity in controls. In the two-stage approach, the first
stage tests the marginal gene-environment association in
a full case-control sample. This test is independent of the
traditional test but assumes that the gene and environ-
ment are not associated in the source population. Again,
simulations have demonstrated that using this approach
results in potential gains in power.
An approach for gene-gene interaction uses the two
marginal gene-disease associations in the first stage.11
Although this is also a two-stage method, it is somewhat
different from the methods discussed here because the
two stages are not independent (although in practice
they are nearly so) and because there is no additional
assumption needed in stage 1. Recent work has adapted
this idea to gene-environment interaction and has shown
that it can offer small improvements over the earlier
method.12
Another two-stage approach has been proposed for case-
control analysis. In this approach, the first stage compares
the deviation from Hardy-Weinberg equilibrium (HWE) in
cases to that in controls.13 The second stage uses a standard
test of the trend in log-odds of disease. This approach is of
limited use in real GWASs because most associations found
to date have followed a log-additive model of risk, undermbridge CB2 0SR, UK; 2Faculty of Epidemiology and Population Health,
Genetics. All rights reserved.
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which both cases and controls would follow HWE and the
first stage would have no power.
In this paper we propose a general formulation of two-
stage approaches in terms of constructing two indepen-
dent estimators of a single quantity. We show how
family-based and gene-environment strategies can be ex-
pressed in this formulation and show how the principle
can be generalized to a wide range of analyses. We focus
on linear models and show that when external reference
information, such as allele frequencies or trait means, is
available, it can serve to improve the power of a GWAS
while retaining robustness to mis-specification of that
information. Illustrating our approach on data from the
Wellcome Trust Case-Control Consortium (WTCCC),14
we identify as significant several regions that were not
significant in the original analysis but whose association
with disease has been validated by follow-up studies.Material and Methods
Construction of Two-Stage Analysis
We consider the analysis of individual markers within a GWAS.
For ease of exposition, we assume the markers are diallelic and
have additive effects on an appropriate scale, but our analysis
and results generalize without difficulty. Suppose we are concerned
with the effect of a marker expressed by a parameter b1. A moti-
vating example is the linear regression model in which the trait
Yof a subject is related to its genotype by EðYjXÞ ¼ b0 þ b1X, where
x denotes the number of minor alleles carried. Then the usual
null hypothesis is H0:b1 ¼ 0, which may be tested by a Wald test
on the maximum likelihood estimator (MLE) bb1. This will form
the basis of the second stage of the analysis.
Suppose that the trait also depends on a nuisance parameter
b0, which we will also estimate from the data. In the linear
regression example, b0 is the intercept. Now let us postulate a
fixed value b0 a priori. If indeed b0 ¼ b0, then
b1 ¼ b1 þ sðb0  b0Þ for any s. Notice that (1) bb1 þ sðbb0  b0Þ andbb1 can be written as A þ B and A  B, where
A ¼ bb1 þ 12sðbb0  b0Þ and B ¼ 12sðbb0  b0Þ and that (2) if bb0 andbb1 areMLEs, thenA and B are asymptotically normally distributed.
If A and B have the same variance and are normally distributed,
then A þ B and A  B are independent. Thus by choosing s such
that var
bb1 þ 12sðbb0  b0Þ

¼ var

1
2
sðbb0  b0Þ

, we can form
an estimator for b1 that is asymptotically independent of bb1.
A calculation gives s ¼ varðbb1Þ=covðbb0; bb1Þ.
We therefore have the following general two-stage procedure:
Stage 1: calculate bb1 þ sðbb0  b0Þ for all markers, where
s ¼ varðbb1Þ=covðbb0; bb1Þ, and let T1 ¼ bb1 þ sðbb0  b0Þ=SEðbb1þ
sðbb0  b0ÞÞ.
Stage 2: for all markers for which jT1j > t1, where t1 is a fixed
threshold, calculate T2 ¼ bb1=SEðbb1Þ. Declare as significant those
markers for which jT2j > t2, where t2 is chosen such that under
H0, PrðjT2j > t2Þ ¼ Ma=m0, where a is the target type 1 error rate
per marker, M is the total number of markers, and m0 is the
number of markers carried forward from stage 1.
The first-stage threshold t1 should be high enough to eliminate
many null markers from stage 2 but low enough to permit mostThe Amassociatedmarkers to pass stage 1. We discuss the choice of t1 later.
The two key properties of this procedure are as follows: (1) if the
postulated value b0 is correct, then bb1 þ sðbb0  b0Þ and bb1 are two
independent estimators of the same quantity b1; and (2) whether
or not b0 is correct, the two estimators remain independent, and
the two-stage procedure maintains the specified type 1 error
rate.10 We note that score or likelihood-ratio tests could be used
in place of T1 and T2 because of their asymptotic equivalence to
theWald tests. TheWald tests are needed for the formal definition
of the procedure because they are independent by construction.
In some circumstances we might be more interested in the
difference between two parameters, b1  b0, in which a postulated
value b0 is again available. An example of such a difference might
be that in allele frequencies between cases and controls. By similar
arguments, we then base stage 1 on
bb1  bb0 þ sbb0  b0;
where
s ¼ var
bb1þ varbb0 2covbb0; bb1
var
bb0 covbb0; bb1 (1)
and stage 2 on bb1  bb0.
The variances and covariances used in the calculation of s
typically dependon the true parameters b0;b1 which are unknown.
Onecan estimate them fromthedata by assuming either thenull or
alternative hypothesis. In common with many standard proce-
dures, we assume the null hypothesis when estimating s, which
also has the effect of reducing or removing any correlation induced
between T1 and T2 by the estimation of standard errors.
We now show how previous two-stage methods can be ex-
pressed in this formulation, and we will then describe some
additional applications.Family-Based Association
Two-stage approaches of this type were initiated by Van Steen
et al.,7 who considered parent-child trios in which markers are
tested for association to a quantitative trait in the children. The
second stage uses the FBAT test,15 whereas the first stage is based
on a ‘‘conditional mean model,’’ which predicts the expected
trait in the child given the parental genotypes. Up to technical
details this approach is equivalent to one based on the orthogonal
linear model of Abecasis et al.16
EðY jX;XM ;XFÞ ¼ mþ bb Bþ bwW;
where B ¼ (XM þ XF)/2, in which XM and XF are the number
of minor alleles in the mother and father, respectively, and W ¼
X  B. The within-family association parameter bw is unbiased
for the additive effect of the minor allele, even under population
stratification, whereas the between-family parameter bb is
confounded by stratification. This model can be rewritten as
EðY jX;XM ;XFÞ ¼ mþ ðbb  bwÞBþ bwX;
from which we see that our two-stage approach uses b1 ¼ bw,
b0 ¼ bb  bw and a postulated value (under no population stratifi-
cation) of b0 ¼ 0. Because bb and bw are independent by construc-
tion, we have s ¼ 1 so that stage 1 is based on bb.
Forbinary traits, a commondesignuses case-parent trios, inwhich
case the above model cannot be used because there is no variation
in Y. Murphy et al.9 propose an approach that is equivalent to
one based on the retrospective full likelihood of Dudbridge17erican Journal of Human Genetics 90, 760–773, May 4, 2012 761
PrðC jM; F;Y ¼ 1Þ ¼ bwXðCÞP $ aM;F
P
c˛SðM;FÞ
bbXðcÞP P ; (2)c˛SðM;FÞ
bwXðcÞ
m;f
am;f
c˛Sðm;f Þ
bbXðcÞ
where C, M, and F are the genotypes of the child, mother, and
father, respectively, X(C) is the number of minor alleles in geno-
type C, S(M,F) is the set of phased genotypes of the possible chil-
dren of parents M and F, and aM;F are additional parameters that
model the mating-type frequencies. In this model, bbw and bbb are
independent, and we can again apply our two-stage approach by
using b1 ¼ bw, b0 ¼ bb  bw, and b0 ¼ 0, which is true under no
population stratification.
Murphy et al. prefer to estimate bb from certain restricted
comparisons of mating-type frequencies and to thus avoid the
need to estimate parameters a, which might be difficult to esti-
mate under latent population stratification. However, their
approach depends on an assumption of HWE in the population,
and such an assumption is itself sensitive to population stratifica-
tion. They give four estimators of bb, but the optimal combination
of these estimators depends on the mating-type frequencies. The
advantages of using estimators of bb that are independent of
a therefore seem limited.
Furthermore, under the commonly assumed multiplicative
model of risk, the relative risk is identified inonly oneof the estima-
tors proposed by Murphy et al. (This estimator is R2 in their Equa-
tion 6).Wewould therefore expect their approach to be less power-
ful than one based on estimating bb from the full data by using the
likelihood (Equation2).Wegiveanumerical example in theResults.
The lackof adistributional theory for theestimatorbasedonR2, and
the fact that this estimator is the solution of a quadratic equation
that might not have real roots, also argue against the use of R2 to
estimate bb. The between-family effect bb is estimated from (Equa-
tion 2) by the UNPHASED software,17 and we can then obtain
a test of bbb ¼ 0 by comparing the likelihoods of the alternative
hypothesis with and without its ‘‘-parentrisk’’ option.
Both quantitative- and binary-trait models can be generalized to
families with multiple siblings and missing parents, but this is not
our focus here. The binary-trait model can be adapted for two-
stage analysis of matched case-control studies because the case-
parent trio design is equivalent to a matched analysis of the case
and three pseudo-controls.18 The details would be straightforward
and are deferred to a future study.
Gene-Environment Interaction
In themethod proposed byMurcray et al., a binary environmental
exposure is considered, and we wish to test whether it modifies the
odds ratio of a genetic marker in a case-control study.10 The first
stage treats the environment as the response and tests for
a marginal association between gene and environment in the
entire sample of cases and controls:
E½logitðPrðE ¼ 1 jXÞÞ ¼ g0 þ ggX (3)
The second stage tests the interaction term in a standard logistic
regression model for case-control data
E½logitðPrðY ¼ 1 jX;EÞÞ ¼ mþ bgXþ beEþ bgeXE
To relate this method to our formulation, we note that the interac-
tion term bge is the same as that in the model with environment as
outcome
E½logitðPrðE ¼ 1 jX;YÞÞ ¼ m0 þ b0gXþ byY þ bgeXY; (4)762 The American Journal of Human Genetics 90, 760–773, May 4, 2so we can base the second stage on Equation 4 by setting b1 ¼ bge.
Under the stage 1 assumption of gene-environment independence
in the population, and under the assumption of a rare disease,
there is no association between the gene and environment in
the controls, so that b0g ¼ 0. Therefore, we can use b0 ¼ b0g with
the postulated value b0 ¼ 0, and we base the first stage on
bge þ sb0g , where s ¼ varðbbgeÞ=covðbbge; bb0gÞ.
This two-stage approach differs from that of Murcray et al., who
base the first stage on the marginal model (Equation 3); the differ-
ence is that we condition on Y in both stages. Indeed, their
marginal parameter gg confounds the parameters b
0
g ;by, and bge,
whereas our scheme estimates bge in both stages. Although the
use of gg gives correct type-1 error rates across the two stages, it
can lead to increased type-1 error rates within stage 1 if b0g and
by are such that ggs0 even while bge ¼ 0. This could lead to
a decrease in power because more null markers might be selected
into stage 2 than expected from the choice of first-stage threshold.
Our proposed approach based on bge þ sb0g does have the expected
type-1 error rate in stage 1 and in that respect is robust to the main
effects bg and be of gene and environment, respectively. In the
Results we give some numerical illustrations of this point.Quantitative-Trait Association
We now consider some applications of our two-stage formulation
to common designs in GWASs. For quantitative traits, a simple test
of association is derived from the linear regression model
EðYjXÞ ¼ b0 þ b1X. The two stages can be based on bb1þ
sðbb0  b0Þ and bb1 as described, but there is a difficulty in specifying
the postulated value of the intercept b0. This is the expected trait
value for carriers of the reference genotype, but this is typically not
known.Wemight, however, have an external estimate of the pop-
ulationmean, and this estimate serves as a good approximation to
b0 when b1 is small. We can therefore apply the two-stage analysis
by using the population mean EðYÞ as b0, but the following
remarks show a limitation of this approach.
The variance-covariance matrix of ðbb0; bb1Þ is
s2

n
P
XP
X
P
X2
1
¼ s
2
n
P
X2  ðPXÞ2
 P
X2 PX
PX n

where s2 is the variance of the trait, n is the number of observa-
tions and the sums are over the sample subjects. Therefore
s ¼ X1, where X is the sample mean of genotype scores X.
Then, conditional on a vector of scores X, the stage 1 estimator
has expectation
E
bb1 þ sbb0  b0 jX ¼ E bb1 þX1bb0  b0 jX
¼ X1EðY jXÞ  b0
Therefore, if EðYjXÞ ¼ b0, the stage 1 statistic has a mean of zero,
whatever the value of b1, and has no power to detect an associa-
tion in the first stage. Under random ascertainment, we have
asymptotically EðYjXÞ ¼ EðYÞ ¼ b0, so we expect the first stage to
contribute no power to the analysis. In practice, we expect the
two-stage analysis to offer a negligible gain in power in a randomly
ascertained sample if we use the population mean for b0.
Two-stage analysis could offer improved power in a sample as-
certained for X because then the expected sample mean EðYjXÞ
differs from the population mean EðYÞ ¼ b0. This would apply to
a ‘‘recall by genotype’’ study, in which subjects carrying particular
rare variants are over-sampled in order to improve the power to
detect their effects. An example not involving genotypes is012
a comparison of transcript levels ðYÞ between normal tissue
samples ðX ¼ 0Þ and abnormal (e.g., tumor) samples ðX ¼ 1Þ;
here the population mean would be an accurate estimate of the
regression intercept b0. These examples are not standard instances
of GWASs because selection on exposures X cannot be done simul-
taneously for all markers. Instead, this approach can be applied to
so-called phenome scans,19,20 in which a limited set of markers X,
on which the sample is selected, are tested for association to a large
set of traits Y, for each of which a population mean is postulated.
Case-control studies are a further example of sample selection, to
be discussed below.
More generally, we may use a generalized linear model to repre-
sent the genotype-trait association
hðEðY jXÞÞ ¼ b0 þ b1X;
where h is an appropriate link function. Here we can again use an
external estimate of the population mean in the postulated value
of b0. For example, for a disease trait the usual link function is the
logit, and we may use the population prevelance EðYÞ to specify
b0 ¼ hðEðYÞÞ. Again, we can expect negligible gain in power under
random ascertainment, although we state this as a conjecture
because there is no general closed form for bb1 þ sðbb0  b0Þ.
Case-Control Studies
The standard analysis of case-control data is a prospective logistic-
regression model:
E½logitðPrðY ¼ 1 jXÞÞ ¼ b0 þ b1X:
Although the data are selected on Y, this model gives the same
inference on b1 as a retrospective model for PrðXjYÞ and is compu-
tationally easier to fit to data. However, the intercept b0 is biased
for the population risk of disease, and the estimate of covðbb0; bb1Þ
is incorrect under case-control sampling. Therefore, naive use ofbb1 þ sðbb0  b0Þ as the stage 1 statistic is problematic.
One solution is to fit the model to the data with the addition of
the fixed offset logðð1 pÞq0=pð1 q0ÞÞ, where p is the proportion
of cases in the sample and q0 is the population prevalence of
disease.21 We can then use bb1 þ sðbb0  b0Þ in stage 1 in the usual
way, by using q0 again in b

0 ¼ logitðq0Þ. However, as we argued
above, this approach would have little power unless there were
also selection for genotypes X.
Alternatively, in stage 1 we can adopt a retrospective model in
which the outcome is genotypes. For simplicity, we describe an
approach that uses alleles as the outcome, which can be easily
generalized to genotypes. Treating alleles now as the sampling
unit, let X ¼ 0 for a major allele and 1 for a minor allele. We fit
the logistic regression model
E½logitðPrðX ¼ 1 jYÞÞ ¼ b0 þ b1Y;
where b0 is now the log-odds of the minor allele in controls. With
an external estimate of the population allele frequency, we can
base stage 1 on bb1 þ sðbb0  b0Þ, where b0 is the logit of the postu-
lated allele frequency. Such estimates are becoming increasingly
available through the growth of biobanks and public repositories
of genotypes from control and population samples. As before,
this approach only has power if the data are selected for Y, which
does indeed apply to a case-control study.
Treating alleles as the response assumes HWE in the population,
and a more robust approach would be to use a generalized logistic
model to treat genotype as a categorical response. Alternatively,
HWE could be incorporated into the stage 1 assumption, andThe Ama robust test from prospective logistic regression (such as the
Armitage trend test) could be used in stage 2.
Many software packages report allele frequencies separately
for the cases and controls, and we can use these separate frequen-
cies to derive a retrospective stage 1 statistic without fitting
a logistic regression model. Let p0 denote the allele frequency in
controls, p1 the frequency in cases, and p* the external estimate
of allele frequency. Then stage 1 can be based on Equation 1, as
follows:
log
bp11 bp0
ð1 bp1Þbp0

þ s log
bp0ð1 pÞ
1 bp0p

;
where
s ¼ varðlogitð
bp1ÞÞ þ varlogitbp0
var

logit
bp0
¼
n11

p11 þ ð1 p1Þ1
	
þ n10

p10 þ

1 p0
1	
n10

p10 þ

1 p0
1	
¼ 1þ n0
n1
;
where n0 and n1 are the numbers of controls and cases, respec-
tively, under the null hypothesis that p0 ¼ p1. Thus, it is straight-
forward to conduct the two-stage analysis of a case-control study
by using the output of packages such as PLINK22 and
UNPHASED.17
For good power, we need the external estimate p* to be close to
the allele frequency in controls p0. If the controls are selected to be
disease free but the external estimate is from the general popula-
tion, then the estimate will be accurate for a rare disease but less
so for a common disease. In Appendix A we show that, when
the controls are screened but the external estimate p* is obtained
from an unselected sample, the first-stage statistic has expectation
zero, and no power, when the prevalence q0 is
q0 ¼
~p

1þ ~p
	1
 p0
p1  p0 (5)
where ~p ¼

p1
1 p1
v
p0
1 p0
1v
with v ¼

1þ n0
n1
1
:
Power Calculations
To illustrate power gains that are possible through a two-stage
analysis, we perform power calculations for a case-control study
by using reference allele frequencies. For this section, let
b0 ¼ logitðp0Þ and b1 ¼ logitðp1Þ. Although b0 is fixed in the anal-
ysis, we assume that it is estimated from an external sample of n0
subjects, and we calculate the expected power over all markers if
there are fixed allele frequencies in cases and controls.
The mean of bb1  bb0 þ sðbb0  b0Þ is
m1 ¼ b1 
n0
n1
b0 þ

1þ n0
n1

b0;
and its variance is
s21 ¼
1
n1p1ð1 p1Þ þ
1
n1p0

1 p0
þ 1þ n0
n1
2
1
n0p

0

1 p0
:
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1F

F1

1 a1
2
	
 m1
s1

þF

F1
a1
2
	
 m1
s1

;
where a1 is a p value threshold for the Wald test of bb1  bb0þ
sðbb0  b0Þ. Similarly, the mean and variance of the second stage
statistic are
m2 ¼ b1  b0
and
s22 ¼
1
n1p1ð1 p1Þ þ
1
n0p0

1 p0
:
If the external sample is from the same population as the sample
at hand, we can assume that stage 1 has the specified type-1 error
rate, and asymptotically the number of markers passing stage 1 is
a1 times the number of null markers. Then the asymptotic proba-
bility of the marker’s passing stage 2 is
1F

F1

1 a
2a1

 m2
s2

þF

F1

a
2a1

 m2
s2

; (6)
where a is the per-marker significance level used in the second
stage.
Because the two test statistics are independent, the overall prob-
ability that a marker will pass both stages is the product of the
probabilities of that marker’s passing each of the two stages. For
given allele frequencies in cases and controls, we can optimize
this power over a1 to determine the optimal stage 1 threshold
for that scenario.
The asymptotic power of detecting the association by a standard
one-stage analysis is
1F

F1

1 a
2
	
 m2
s2

þF

F1
a
2
	
 m2
s2

:
We compared the power of one- and two-stage analysis for
minor allele frequencies (MAFs) in the range 0–0.5 and odds ratios
in the range 1.0–1.5. We also varied the size of the external refer-
ence sample from 1,000–20,000 subjects to study its effect on the
overall power.
We first performed these comparisons under the assumptions
that the external reference sample is from the same population
as the sample at hand and that the disease is rare. Under these
assumptions, the postulated allele frequencies in controls are accu-
rate, ie. b0 ¼ b0.
To consider a mismatch between reference and sample popula-
tions, we then used Wright’s separation statistic FST as a measure
of distance between populations. The Balding-Nichols model is
often used for modeling the MAFs in two or more populations
when FST > 0.
23 This model assumes a background allele
frequency p. Then the MAFs in different populations are modeled
as independent Beta ðpð1 FST Þ=FST ; ð1 pÞð1 FST Þ=FST Þ random
variables.
To determine the probability of rejecting the null hypothesis for
a SNP with background allele frequency p in the presence of pop-
ulation separation FST , we integrated over the distribution of refer-
ence and sample population frequencies:
Prðreject H0 j p; p1Þ ¼
ZZ
Pr

reject H0 j p0; p0; p1

f

p0

f

p0

dp0dp

0;
(7)
where f is the probability density function for a Beta
ðpð1 FST Þ=FST ; ð1 pÞð1 FST Þ=FST Þ random variable. The rejec-764 The American Journal of Human Genetics 90, 760–773, May 4, 2tion probability in stage 1 is as given in Equation 7, and this is esti-
mated for all null SNPs to obtain the actual type-1 error rate which
is substituted for a1 in Equation (6). We consider the effect on
power of using reference populations with separation ranging up
to FST ¼ 0:1, the order of magnitude separating populations on
different continents.24
We finally considered the effect on power when the disease is
not rare, the controls are screened, and the reference individuals
are unscreened, so that the control allele frequencies depart
from the population frequencies. Assuming a well-matched refer-
ence population ðFST ¼ 0Þ, we have
p0 ¼ ð1 expitðgþ b1  b0ÞÞp

0
ð1 expitðgþ b1  b0ÞÞp0 þ ð1 expitðgÞÞ

1 p0
;
where g is chosen so that the denominator is 1 minus the popula-
tion prevalence of disease. We considered the full range of preva-
lence and again substituted the estimated type-1 error rate from
stage 1 for a1 in Equation 6.Analysis of WTCCC Data
We applied the analysis described above to data from the Well-
come Trust Case-Control Consortium.14 Although this dataset
has been well studied, it serves our illustrative purposes well
because several diseases were studied under a common design
and because follow-up studies have identified further loci that
were missed by the initial scan. Furthermore, there is a natural
reference panel from which to draw postulated allele frequencies
for eachmarker, but some these frequenciesmight not be accurate.
In the WTCCC study, about 2,000 cases from seven common
diseases were each compared to a common control sample of
about 1,500 UK blood donors and 1,500 members of the 1958
British Birth Cohort. For each disease, we combined the cases of
the six other diseases to form a reference panel from which the
population allele frequencies were then postulated. We expect
these frequencies to be accurate for most markers, but not for
those that have true disease associations; however, the two-stage
analysis is robust to such deviations. Therefore, for each disease
there are about 2,000 cases and 3,000 controls on which the stage
2 analysis is performed, and there is a reference panel of about
12,000 cases, which is used for obtaining the postulated frequen-
cies used in stage 1.
In addition to the quality-control filters applied in the original
study, for each disease we removed SNPs with a MAF < 1% or
a genotype missing rate > 1% in any of the case, control, or refer-
ence samples. This led to an average over the seven diseases of
344,087 autosomal SNPs analyzed. In line with the original study,
we applied an overall significance level per SNP of p < 5 3 107.
We set the first-stage threshold at c2 ¼ 5 (p ¼ 0.025), which corre-
sponds to values giving optimal power over realistic effect sizes
(see Results). For SNPs that pass the first stage, this gives an ex-
pected stage 2 threshold of about 2 3 105, considerably more
lenient than the standard analysis threshold.Selection of Markers from Stage 1
We conclude this section with some remarks on the principled
selection of markers from the first stage. We have discussed
a scheme based on thresholding a statistic in the standard fre-
quentist approach. This is the method employed by Murcray
et al. for gene-environment interaction,10 and those authors
proved that it maintains the family-wise type-1 error rate over
the two stages. Other authors have suggested schemes based on012
selecting a fixed number of top-ranking markers7 or based on se-
lecting all markers into stage 2 but weighting them according to
their ranks in stage 1.8
It is helpful to view the two-stage analysis from a Bayesian
perspective, in which the prior odds of a marker association are
modified by the first stage to become the prior odds in the second
stage. When one is inferring significance from frequentist tests,
the posterior and prior odds of association are related by
PrðH1 jT > tÞ
PrðH0 jT > tÞ ¼
PrðT > t jH1Þ
PrðT > t jH0Þ
PrðH1Þ
PrðH0Þ;
where T > t denotes a significant test statistic. The first term in the
right-hand side is the ratio of the power to the type-1 error rate.
The low significance thresholds applied to markers in GWASs
reflect low prior odds of association: if we assume a reasonable
power to detect an effect, a low type-1 error rate is needed to
ensure reasonable posterior odds.25
We can use obvious notation to indicate that, in a two-stage
design,
PrðH1 jT1 > t1;T2 > t2Þ
PrðH0 jT1 > t1;T2 > t2Þ ¼
PrðT1 > t1 jH1Þ
PrðT1 > t1 jH0Þ
PrðT2 > t2 jH1Þ
PrðT2 > t2 jH0Þ
PrðH1Þ
PrðH0Þ
because the two stages are independent. Because the second-stage
threshold is defined by PrðT2 > t2jH0Þ ¼ Ma=m0, it follows from
Slutsky’s theorem that PrðT1 > t1jH0ÞPrðT2 > t2jH0Þ%a, with
equality when H0 holds for all markers. That is, each individual
marker has the same type-1 error rate in both one- and two-stage
analyses. Any differences in power between one- and two-stage
analyses therefore translate directly to differences in posterior
odds, and we can directly compare the power of the two
approaches.
This observation deals with a possible objection that stage 2
does not comprise a reduced number of hypothesis tests because
stage 1 does not formally reject any hypotheses. We see here
that, as long as the actual type 1 error rate in stage 1 (i.e.,
PrðT1 > t1jH0Þ) is consistently estimated by m0=M, the proportion
of markers carried forward, the prior odds are modified appropri-
ately by what amounts to an empirical Bayes adjustment. Thus,
there is no fundamental problem with the two-stage analysis
from a Bayesian perspective.
The rank-based schemes7,8 need further consideration. Fixing
the number of markers carried forward can be viewed as a crude
way of controlling the type 1 error rate in stage 1; it is useful
when there is no distributional theory for the stage 1 statistic, as
in the method of Van Steen et al. However, this approach seems
unnecessary under the (semi-) parametric models we have
described. Using all markers in a stage 2 weighted analysis encodes
a belief that the weights correspond to the odds of association. In
particular, the exponential weighting developed by Ionita-Laza
et al.8 reflects belief in a specific model in which a small number
of markers have strong effects and a greater number of markers
have weak effects. It is notable that the simulations reported by
those authors considered only the situation in which there is
exactly one associated SNP. Because the same set of weights would
be derived for any dataset, this approach seems untenable for ob-
taining inferences that are well calibrated against fixed prior odds.
Another scheme that uses stage 1 ranks in a joint analysis of the
two stages26 is potentially sensitive to the stage 1 assumption,
although the authors of that study showed that it is acceptably
robust in family-based studies. We wish to consider the merits of
the two-stage design per se separately from those available fromThe Amexploiting prior beliefs, and for this reason we focus on selection
based on p value thresholding in stage 1.
Ionita-Laza et al.8 also propose using the estimated second-stage
power as the first-stage statistic. This approach effectively substi-
tutes the standard error of the stage 2 estimator into the stage 1
statistic and is particularly useful for family-based designs because
the standard errors of the between- and within-family parameters
could differ considerably. In general, however, the standard errors
of the stage 1 and 2 statistics could be highly correlated, as could
be their estimators. There might therefore be little gain in power,
or a possible loss of independence between the two stages. Again,
this approach has merit in some applications, but we caution
against its adoption as a general strategy.Results
Family-Based Association
We report a brief comparison between the approach
proposed by Murphy et al.9 for discrete traits (this
approach is henceforth denoted MWL on the basis of the
authors’ initials) and the one we propose in which the first
stage is based on bbb in Equation 2. We simulated 1,000
case-parent trios under a disease model consisting of
a single risk SNP with a multiplicative allelic relative risk
of 2 and a risk allele frequency of 0.3 in a randomly mating
population. Under this model, the only informative esti-
mator of MWL is the one derived from R2 in Murphy
et al.’s Equation 6. Across 10,000 simulated datasets, the
mean of the relative risk estimated from R2 was 2.31, and
the empirical 95% confidence interval was (1.22, 3.89).
The exponentiated mean of bbb was 1.88, and the empirical
95% confidence interval was (1.00, 3.10), showing that our
estimator has greater precision.
We also performed 10,000 simulations under the null
hypothesis with a relative risk of 1. The mean of the rela-
tive risk estimated from R2 was 2.06, and the empirical
95% confidence interval was (1.16, 3.51). This suggests
that R2 confers a finite-sample bias in the estimator. The
exponentiated mean of bbb was 1.29, and the empirical
95% confidence interval was (0.99, 2.55). This also
suggests a bias, but it is more likely a result of numerical
difficulties in estimating bbb around the null hypothesis
(we used the Nelder-Mead algorithm), also noted in
MWL. Both methods therefore have limitations, but our
approach achieves greater separation between the null
and alternative distributions of the stage 1 statistics, and
this greater separation implies greater power.Gene-Environment Interaction
We compared the approach of Murcray et al.10 (this
approach is henceforth denoted MLG), which is based on
the marginal model (Equation 3) in stage 1, with the
approach we suggest in which both stages condition on
the case-control status (Equation 4). In Table 1 we show
power estimates under some of the same conditions as in
Table 1 of Murcray et al. The two-stage methods have
similar power in most situations, except when there iserican Journal of Human Genetics 90, 760–773, May 4, 2012 765
Table 1. Power Comparison of Gene-Environment Testing
Procedures
Disease
Model
One-Stage
Power
Two-Stage
Power
MLG
Power Correlation
Base 0.322 0.5664 0.5764 0.0007
qa ¼ 0:1 0.1579 0.3654 0.373 0.011
qa ¼ 0:3 0.3023 0.5306 0.5572 0.004
pe ¼ 0:1 0.0379 0.1194 0.1193 6 3 106
pe ¼ 0:25 0.2235 0.4548 0.4567 0.012
Re ¼ 2 0.2181 0.3938 0.4554 0.008
Rg ¼ 2 0.2812 0.519 0.5433 0.0009
Rg ¼ Re ¼ 2 0.1449 0.3224 0.4001 0.0027
pge ¼ 0:01 0.3159 0.5568 0.5563 0.0007
pge ¼ 0:05 0.3175 0.511 0.5215 0.0009
pge ¼ 0:3 0.3138 0.3969 0.4043 0.0017
pge ¼ 0:95 0.2986 0.2956 0.3015 0.0038
Comparison of the standard test of gene-environment interaction (one-stage
power) with proposed two-stage tests (two-stage power) and the two-stage
method of Murcray et al. (MLG power). qa: frequency of risk allele. pe:
frequency of risk environment. Rg : main effect of genetic exposure, dominant
model. Re: main effect of environmental exposure. Rge: gene-environment
interaction. pge: proportion of null markers with a population gene-environ-
ment odds ratio of 2. Base: baseline model with qa ¼ 0:2, pe ¼ 0:5, Rg ¼ 1,
Re ¼ 1, Rge ¼ 3, and pge ¼ 0. There were 500 cases, 500 controls, and
10,000 null markers; a1 ¼ 0:05. Power was estimated from 10,000 replicates
(SE < 0.005). Correlation: correlation between stage 1 and 2 statistics of our
method when Rge ¼ 1.
Table 2. Power Comparison of Gene-Environment Testing
Procedures When There Are Marginal Genetic Effects
Re m
One-Stage
Power
Two-Stage
Power
MLG
Power
Type-1 Error Rate
of MLG Stage 1
2 0 0.1697 0.3266 0.3918 0.05
5,000 0.1697 0.3266 0.3407 0.0925
10,000 0.1697 0.3266 0.3105 0.135
0.5 0 0.2907 0.5269 0.5339 0.05
5,000 0.2907 0.5269 0.4724 0.1013
10,000 0.2907 0.5269 0.428 0.1525
Comparison of one-stage, proposed two-stage, and MLG methods when
Rg ¼ 2 for m of the 10,000 null markers and Rg ¼ 1 for the rest. Other param-
eters are as in the ‘‘base’’ in Table 1. Power was estimated from 10,000 repli-
cates (SE < 0.005).a main environmental effect, in which case the MLG
method has greater power than our method. When the
null hypothesis is true, the two stages of our method are
uncorrelated, as expected, from which it follows that the
family-wise type-1 error is controlled at the specified
rate.10
We compared the methods under some further condi-
tions. First, we give an example in which our method has
greater power than MLG. The model is the same as the
baseline in Table 1, except that the environmental main
effect is 1/6. The one-stage analysis has an estimated power
of 0.2187, our two-stage analysis 0.4068 and the MLG
method 0.3359. This result arises from the opposite direc-
tions of the main and interaction effects, which are
confounded in the MLG method.
We then considered the type 1 error rate in the first stage
when there are both genetic and environmental main
effects. When both gene and environment had a main
effect of 2 but there was no gene-environment interaction,
then stage 1 of MLG had an estimated type 1 error rate of
0.135 at p ¼ 0.05. When the environmental main effect
was changed to 1/2, the estimated type 1 error rate was
0.1525. We therefore expect MLG to carry more markers
into stage 2 than our method, which maintained the
nominal type-1 error rate in stage 1. In Table 2 we show
power comparisons when there is a main environmental
effect and when none, half, or all of the null markers766 The American Journal of Human Genetics 90, 760–773, May 4, 2have a genetic main effect. We see that the power of
MLG is reduced as more null markers have a main genetic
effect, and the relative power of MLG to our method
depends both on the number of such markers and on the
size and direction of the main environmental and interac-
tion effects.
These results suggest that MLG has slightly higher power
than our approach when there are no main effects. It can
have significantly greater power when there is a main envi-
ronmental effect in the same direction as the interaction,
but it will have lower power if the main and interaction
effects are in opposite directions. Its power is further
reduced if there are many SNPs with genetic main effects
but no interaction effects. Because the true set of
genome-wide main and interaction effects is unknown
a priori, it is impossible to know which method would be
more powerful on a given dataset. Our approach can be
recommended because it targets the interaction effect
more directly and has consistent power over a range of
scenarios. A hybrid approach might be a useful direction
for further development.12
Case-Control Analysis
We consider the power of a two-stage analysis in which
external estimates of allele frequencies are available for
use in stage 1. We followed the set-up of our analysis of
the WTCCC data and assumed 2,000 cases, 3,000 controls,
and an external reference of 12,000 individuals and
344,087 SNPs. For comparison with the WTCCC study,
we required an overall significance level per SNP of a ¼
5 3 107.
Figure 1 compares the power of the two-stage approach
with that of the one-stage approach as the odds ratio at
the associated SNP changes. The MAF of the causal SNP
in controls is set to 0.25, and the first-stage significance
level a1 is set to 0.025. We chose this value to maximize
the power over a range of possible MAFs and odds ratios
of the causal SNP (Table 3). The two-stage procedure has
80% power to detect association for causal SNPs with
odds ratios of 1.287 or more. For the same power, the012
Figure 1. Effect of Odds Ratio on the Power of One-Stage and
Two-Stage Procedures
Power of one-stage (dashed) and two-stage (solid) tests as a func-
tion of the odds ratio of the causal SNP. MAF of causal SNP:
0.25. There were 2,000 cases, 3,000 controls, a reference panel of
12,000 individuals, and 344,087 null markers. a1 ¼ 0:025.
Table 3. Optimal Values of a1 for Different Sizes of the Causal
Effect
Odds Ratio
Minor Allele Frequency
0.05 0.1 0.25 0.5
1.1 0.0271 0.0178 0.0152 0.0145
1.2 0.0216 0.0192 0.0199 0.0207
1.3 0.0244 0.0239 0.032 0.0389
1.5 0.0353 0.0479 0.0114 0.0114
There were 2,000 cases, 3,000 controls, a reference panel of 12,000 individ-
uals, and 344,087 null markers.one-stage procedure requires an odds ratio of 1.317 or
more.
Figure 2 shows the power of the two procedures as the
MAF of the causal SNP changes. The odds ratio is fixed at
1.3. Both Figures 1 and 2 show that a substantial increase
in power is possible with the two-stage procedure.
However, the size of the reference panel is larger than
might be feasible in some applications. We therefore inves-
tigated how the power changes as the size of the reference
panel changes for a fixed value of a1. Figure 3 shows that
the power of the two-stage procedure is lowwhen the refer-
ence set is small. The size of the reference set determines
the precision of b0 and, thus, the variance of the first-stage
test statistic. Because the mean of the first-stage test
statistic remains unchanged, an increased variance gives
lower power for the first-stage test. For a1 ¼ 0.025, at least
4,000 individuals are needed for the power of the two-stage
procedure to be higher than that of the one-stage proce-
dure. This is larger than the sizes of the HapMap and
1000 Genomes databases, which are natural choices for ob-
taining reference allele frequencies. Instead, the most
useful sources are other GWASs using the same markers,
which is not a strong restriction given the industry stan-
dardization of marker panels.
On the other hand, diminishing returns means there is
little advantage to going beyond 15,000 individuals in
the reference set. For smaller or larger reference sets, one
can vary the value of a1 to maximize the power of the
two-stage approach. Table 4 shows the optimal value of
a1 for different reference set sizes if the power to detect
a variant with frequency 0.25 and odds ratio 1.3 is to be
maximized. Note that a1 ¼ 1 will reduce the two-stage
procedure to the traditional one-stage test but give the
same power.
In Figure 4 we show how the power of the two-stage
approach depends on the significance level used in the first
stage. The power increases sharply to amaximum and thenThe Amdecreases gradually. For this particular set of parameters,
the optimal significance level is 0.0143, but this will differ
according to the odds ratio, MAF, and number of SNPs
being tested. It is interesting to note that the power
decreases gradually as a1 increases, so the two-stage
approach is quite robust to the choice of a1 so long as it
is sufficiently high.Power when Reference and Test Populations Differ
When the reference population is different from the test
population, the postulated allele frequencies will no longer
match the frequencies in the controls. This will affect both
the number of null markers being tested at the second
stage and the probability that an associated marker will
get through stage 1. We consider a uniform distribution
of background allele frequencies between 0.05 and 0.5, as
well as control and reference frequencies that follow the
Balding-Nichols model described in the Material and
Methods. Table 5 shows the expected number of null
markers at the second stage, as well as the power of the
one- and two-stage tests, for a series of values of the popu-
lation separation FST .
Table 5 shows that as FST increases, the expected number
of null SNPs getting through to the second stage increases
rapidly. As a result, the multiple test correction applied at
the second stage increases and the second-stage power
decreasesmonotonically. On the other hand, the first-stage
power decreases monotonically and then increases again.
This seems surprising, but it occurs because the power
function of the first stage is not symmetric in the MAF
around the background value. This result also assumes
that the odds ratio does not vary with the control MAF.
The two-stage analysis remains more powerful than the
one-stage analysis for values of FST less than 10
3, which
is the order of magnitude of separation between popula-
tions within Europe. It is clearly important that the refer-
ence population be a close match to the sample at hand.Power when Reference Sample Is Unscreened
for Disease
Another scenario that leads to different MAFs between the
control and the reference samples is when the controls are
screened to be free of disease but the reference set iserican Journal of Human Genetics 90, 760–773, May 4, 2012 767
Figure 2. Effect of the MAF of the Causal SNP on the Power of
One-Stage and Two-Stage Procedures
Power of one-stage (dashed) and two-stage (solid) tests as a func-
tion of the MAF of the causal SNP. Odds ratio of the causal SNP:
1.3. There were 2,000 cases, 3,000 controls, a reference panel of
12,000 individuals, and 344,087 null markers. a1 ¼ 0:025.
Table 4. OptimalValuesofa1 forDifferentSizesof theReferenceSet
Size of
Reference Set Optimal a1
Power of
Two-Stage Approach
1,000 1 0.714
2,500 0.304 0.747
5,000 0.1 0.803
10,000 0.036 0.852
15,000 0.022 0.873
20,000 0.018 0.885
MAF of the causal SNP: 0.25. Odds ratio of the causal SNP: 1.3. There were
2,000 cases, 3,000 controls, and 344,087 null markers.unscreened. The result of this will be that the frequency in
the reference set is a weighted sum of the frequency in
screened controls and the frequency in cases; the weight
will depend on the disease prevalence. Again, the differ-
ence between the postulated and actual allele frequencies
will increase the number of null markers tested in the
second stage and affect the power but not the type 1 error
rate.
The degree to which this factor affects the power will
depend on the prevalence of the disease. If the phenotype
is rare, then the reference set will consist mostly of
unaffected individuals, and the MAF will be close to that
of the controls. If the phenotype is more common, the
power of the first stage can be severely affected. Figure 5
shows the power of the two-stage test procedure as the
prevalence of the disease changes for a1 ¼ 0.025, popula-Figure 3. Effect of the Size of the Reference Set on the Power of
the Two-Stage Procedure
Power of one-stage (dashed) and two-stage (solid) tests as the size
of the reference set varies. MAF of the causal SNP: 0.25. Odds ratio
of causal SNP, 1.3. 2000 cases, 3000 controls, 344087 null markers,
a1 ¼ 0:025.
768 The American Journal of Human Genetics 90, 760–773, May 4, 2tion MAF ¼ 0.25, odds ratio ¼ 1.3, and other parameters
as before. Note that the prevalence does not change the
MAF of the screened controls, so the power of the one-
stage test procedure is constant.
Figure 5 shows that this factor can lead to a disastrous
loss of power when the disease prevalence is high. The
power is at its lowest when the prevalence is close to 0.4,
which is also the proportion of cases in the sample. In
fact, for the above parameters, the formula in Equation 5
gives the minimum power at a prevalence of 0.386. We
see that, similar to the exact result we obtained for linear
regression, the first stage has no power when the case
sampling fraction is close to (although not exactly equal
to) that achieved under random ascertainment.Analysis of WTCCC Data
We analyzed each of the seven diseases in theWTCCC data
by using the other six sets of cases as an external reference
panel. Table 6 shows the total number of significant SNPs
in each disease. There is variation in the relativeFigure 4. Effect of the First-Stage Significance Level on the
Power of the Two-Stage Procedure
Power of one-stage (dashed) and two-stage (solid) procedure as the
first-stage significance level varies. MAF of the causal SNP: 0.25.
Odds ratio of the causal SNP: 1.3. There were 2,000 cases, 3,000
controls, a reference panel of 12,000 individuals, and 344,087
null markers.
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Table 5. Power Comparison when Reference and Control
Populations Are Different
FST E (m0)
First-Stage
Power
Second-Stage
Power
Overall
Two-Stage
Power
One-Stage
Power
0 10,141 0.951 0.906 0.861 0.712
105 14,345 0.949 0.895 0.849 0.626
104 56,263 0.900 0.828 0.746 0.625
103 203,358 0.727 0.748 0.554 0.623
102 303,153 0.794 0.701 0.564 0.606
101 338,330 0.932 0.571 0.527 0.506
Power of one- and two-stage test procedures as a function of separation FST
between sample and reference populations. Eðm0Þ: expected number of
markers carried forward from stage 1.
Table 6. Numbers of Genome-wide Significant SNPs in One- and
Two-Stage Analysis of the WTCCC Data
Disease One-Stage Two-Stage
Size
Stage 1
Size
Stage 2 Correlation
BD 2 1 341,890 11,824 0.0065
CAD 20 10 345,460 10,477 0.0009
CD 68 72 345,628 11,199 0.008
HT 3 2 343,615 10,085 0.0045
RA 174 165 343,672 11,087 0.0021
T1D 471 500 344,684 11,372 0.0024
T2D 18 34 343,658 11,065 0.0011
Total 756 784
Abbreviations are as follows: BD, bipolar disorder (BPAD; [MIM 125480]); CAD,
coronary artery disease; CD, Crohn disease (CD; [MIM 266600]); HT, hyper-
tension (HTN; [MIM 145500]); RA, rheumatoid arthritis (RA; [MIM 180300]);
T1D, type-1 diabetes (T1DM; [MIM 222100]); and T2D, type-2 diabetes
(NIDDM; [MIM 125853]). Numbers include SNPs that passed initial quality
control but were later discarded after inspection of cluster plots. Size stage 1:
the number of SNPs included in the first stage. Size stage 2: the number of
SNPs carried forward into the second stage. Correlation: correlation between
stage 1 and stage 2 statistics for SNPs with p > 0.05 in stage 2.performance of one- and two-stage analyses, but over all
seven diseases there is a higher total of significant associa-
tions from the two-stage analysis. Among SNPs that were
not nominally significant in stage 2, the stage 1 and 2
statistics were uncorrelated, as expected.
There were eight regions that were significant in the two-
stage but not the one-stage analysis; they are summarized
in Table 7. Each of the regions has been subsequently
validated in an independent GWAS or a meta-analysis.
The regions were slightly short of significance in the one-
stage analysis, but all bar one had been marked as sugges-
tive in the WTCCC paper. Because of the reduced multi-
plicity in the second stage (equivalently, the increased
prior odds), these markers became genome-wide signifi-
cant under our approach. We computed an adjusted
p value for each of these markers by multiplying the stage
2 p value by the ratio of the number ofmarkers in stage 2 to
the number in stage 1. This gives a p value that is calibratedFigure 5. Effect of Disease Prevalence on the Power of the Two-
Stage Procedure
Power of one-stage (dashed) and two-stage (solid) test statistics
when controls are screened and reference-set individuals are not
and as the prevalence of the disease varies. MAF of the causal
SNP: 0.25. Odds ratio of the causal SNP: 1.3. There were 2,000
cases, 3,000 controls, a reference panel of 12,000 individuals,
and 344,087 null markers. a1 ¼ 0:025.
The Amagainst the initial prior odds, and as such it can be directly
compared to the p value from a one-stage analysis. Table 7
shows that the adjusted p values are genome-wide sig-
nificant when the one-stage p values are not.
There were three regions that were significant in the
one-stage but not the two-stage analysis; they are summa-
rized in Table 8. Here, the regions were eliminated in the
first stage, even though the second-stage analysis was
genome-wide significant. These regions, too, have been
subsequently validated, so that they represent false nega-
tives of the two-stage analysis. Two of these might be due
to a shared genetic basis between inflammatory bowel
disease (IBD; [MIM 266600]) and type-1 diabetes (T1DM;
[MIM 222100]); rs2542151 has been independently
associated with T1DM,27 and rs17388568 has been inde-
pendently associated with ulcerative colitis (UC; [MIM
191390]).28 In all three cases the reference frequencies
are closer to the case frequency than to the control
frequency, reducing the significance of the stage 1 test.Discussion
We have given a general description of two-stage analysis
of GWAS data; this analysis includes previously developed
applications to family-based association and gene-environ-
ment interaction testing. With regard to the former, we
recover previous work exactly, whereas for the latter we
obtain an alternative approach. In both cases our formula-
tion offers new insights and potential advantages over
previous methods. Our general description opens up
a range of possible further applications. It can be applied
to any analysis that both involves testing a normally
distributed parameter estimator and depends on a nuisanceerican Journal of Human Genetics 90, 760–773, May 4, 2012 769
Table 7. Regions that Were Genome-wide Significant in Two-Stage Analysis but Not in One-Stage Analysis
Disease
Chromo-
some Lead SNP Mb Stage 2
Adjusted
Stage 2 WTCCC
Case
Frequency
Control
Frequency
Reference
Frequency
Other
WTCCC Replication
CD 3 rs9858542 49.68 7.23 3 107 2.19 3 108 7.71 3 107 0.330 0.282 0.285 Genotypic
test,
expanded
controls
Franke31
CD 6 rs7768538 32.84 1.76 3 106 5.34 3 108 8.65 3 10-7 a 0.412 0.463 0.468 Franke
CD 21 rs2836754 39.21 1.04 3 105 3.15 3 108 n/a 0.399 0.353 0.352 Expanded
controls
Frankeb
RA 6 rs5029939 138.24 8.48 3 106 2.74 3 107 4.99 3 10-6 [a] 0.055 0.036 0.035 Stahl32
T1D 10 rs10795791 6.15 1.16 3 105 3.81 3 107 7.96 3 106 0.456 0.411 0.414 Expanded
controls
Barrett33
T2D 2 rs6718526 161.04 3.06 3 106 9.85 3 108 2.4 3 106 0.171 0.209 0.205 Expanded
controls
Qi34
T2D 6 rs9465871 20.83 5.69 3 106 1.83 3 107 1.00 3 10-6 a 0.218 0.178 0.182 Genotypic
test
Zeggini35
T2D 12 rs1495377 69.86 1.47 3 106 4.73 3 108 1.31 3 106 0.547 0.497 0.502 Expanded
controls
Zeggini
Disease abbreviations are as in Table 6. Stage 2: p value from allelic Wald test in the second stage. Adjusted stage 2: p value from stage 2 multiplied by the ratio of
the number of SNPs in stage 2 to the number in stage 1. WTCCC: p value from trend test reported in WTCCC paper. Case frequency: allele frequency in the cases.
Control frequency: allele frequency in the controls. Reference frequency: allele frequency in the combined cases of the other six diseases. Other WTCCC: other
tests performed in the WTCCC study in which the SNP had genome-wide significance. Replication: source of subsequent validation of this association.
ap value for a different SNP in the same region.
bReplication was 5 Mb from this SNP.parameter for which a reasonable value can be postulated.
This includes many common parametric and semipara-
metric models.We have considered semiparametric formu-
lations of linear and logistic regression and have shown
that if the population mean is used as a postulated value
of the intercept, then two-stage analysis can offer increased
power if there is selection on the independent variables.
This approach might therefore hold promise for studies
such as recall-by-genotype phenome scans, comparisons
of disease-selected and -unselected subjects, and case-
control studies of rare disease. It could also be applicable
to analysis of secondary quantitative traits in case-control
samples, although the appropriate specification of a postu-
lated nuisance parameter is not obvious and is left to future
work.
Focusing on standard case-control studies, we propose
a first-stage statistic that incorporates an external estimate
of the allele frequency. We have shown that if MAFs in the
external reference set have the same underlying mean as
those in the controls, then there is scope for a significantTable 8. Regions that Had Genome-wide Significance in the WTCCC S
Disease Chromosome Lead SNP Mb Stage 1 Case Frequ
CD 5 rs1000113 150.22 0.74 0.098
CD 18 rs2542151 12.77 0.22 0.209
T1D 4 rs17388568 123.69 0.44 0.307
Stage 1: p value from first stage analysis. Case frequency: allele frequency in the c
allele frequency in the combined cases of the other six diseases. Replication: sour
770 The American Journal of Human Genetics 90, 760–773, May 4, 2gain in power via the two-stage approach. This condition
requires that the reference set and controls be from the
same population and that either the disease is rare or
both sets be unscreened (or both be screened) for the
disease. As the separation between the populations
increases, the power gain rapidly diminishes and becomes
a power loss when the separation is greater than that typi-
cally found between European populations. Furthermore,
if the controls are screened for disease and the reference
individuals are unscreened, then the power can be severely
diminished for certain values of the disease prevalence.
The size of the reference set and the sample at hand also
need to be of similar sizes, so resources such as the
HapMap and 1000 Genomes databases may not be suffi-
cient. Although these factors might seem like significant
drawbacks, the sheer number of datasets becoming avail-
able makes it likely that several suitable reference sets
will be possible for each case-control study.
In principle, our approach can be applied with summary
data only and does not require individual subject data.tudy but Not in the Two-Stage Analysis
ency Control Frequency Reference Frequency Replication
0.067 0.076 Franke31
0.163 0.173 Franke
0.260 0.283 Barrett33
ases. Control frequency: allele frequency in the controls. Reference frequency:
ce of subsequent validation of this association.
012
However, if covariates are included in themodel, as is often
done as a means of controlling for population stratifica-
tion, then individual data will be needed. There is no
problem in principle with applying our approach with co-
variates because we can simply test our parameters after
including covariates in the model. It might be necessary
to rescale or recode covariates so that the external reference
value corresponds to a parameter in the model, for
example the MAF in a particular sub-population. The
allowance for covariates is another advance on previous
methods.
Of course, greater improvements in power are possible
from a joint analysis of the two stages when the assump-
tion in the first stage is explicitly controlled for.4,29 This
was done in the WTCCC study, when cases from clinically
distinct diseases were pooled with the controls so that the
total sample size increased. These ‘‘expanded controls’’
analyses detected some, but not all, of the additional asso-
ciations we found via two-stage analysis. However, our aim
is to show the utility of external summary data, when
available, while retaining robustness to a mismatch
between the external data and the sample at hand. We
expect that reference databases of allele frequencies will
become available without the individual genotypes that
would allow statistical methods to adjust for population
differences between reference and sample data. We aim
to show how these data can improve standard GWAS anal-
ysis without incurring bias.
Our WTCCC analysis is the first application of two-stage
analysis to multiple datasets and confirms the higher
power of this approach. We detected eight true positives
that were missed by standard analysis. Although our
two-stage analysis missed three associations that were
detected by standard methods, two of these can be attrib-
uted to the choice of reference panel, which includes cases
from related diseases, a situation that need not occur in
general.
Two-stage approaches have been described as
‘‘screening’’ followed by ‘‘replication.’’4,7,9 We discourage
this usage because, in our view, replication involves con-
firming a specific hypothesis that has already been firmly
established. In contrast, the first of our two stages merely
selects a subset of markers and does not formally generate
hypotheses for testing. However, we have noted that the
evidence for association is modified to a degree by the first
stage, to which the second is adaptive in its adjustment for
multiplicity.
Bayesian methods offer an alternative approach to
including assumed values of model parameters but still al-
lowing for uncertainty in the assumptions.30 At one
extreme, an uninformative prior distribution on the
nuisance parameter corresponds to a one-stage analysis,
whereas at the other, a highly informative prior distribu-
tion corresponds to a joint analysis of the two stages. In
the situations we have considered, we can expect the stage
1 assumptions to hold for somemarkers and not for others.
A prior distribution that reflects this property and correctlyThe Ammodels departures from the assumption should lead to
a more powerful analysis than our two-stage approaches.
Our methods are a compromise that improves power by
including prior information on nuisance parameters while
retaining robustness to mis-specification of that informa-
tion. In this respect, two-stage and Bayesian analyses
are alternative approaches that offer different advantages
according to context.
In practice, standard one-stage analyses are unlikely to
be discarded even if more powerful alternatives are avail-
able. However, we think that two-stage analysis should
join the array of complementary methods that can be
applied after initial simple analyses are completed. We
have given a general account of this approach, as well as
its advantages and limitations, and hope that this will
stimulate its further study and use in a wider range of
applications.Appendix A
Effect of Prevalence on Power in Case-Control Studies
In terms of the allele frequencies p0 and p1, the number of
controls and cases n0 and n1, and the prevalence q0, the
expectation of the stage 1 statistic is
log

p1

1 p0

ð1 p1Þp0

þ

1þ n0
n1

log

p0

1 q0p1 

1 q0

p0

1 p0

q0p1 þ

1 q0

p0
:
Therefore, the value of q0 that gives mean 0 solves the
following equation:
log

q0p1 þ

1 q0

p0
1 q0p1 

1 q0

p0

¼ n log

p1

1 p0

ð1 p1Þp0

þ log

p0
1 p0
;
where v ¼ ð1þ n0=n1Þ1. Then
q0p1 þ

1 q0

p0
1 q0p1 

1 q0

p0

¼

p1
1 p1
v
p0
1 p0
1v
h~p;
and therefore ~p=1þ ~p ¼ q0p1 þ ð1 q0Þp0, giving q0 ¼
~pð1þ ~pÞ1  p0=p1  p0.Acknowledgments
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